Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: A phase I study

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1961-1966

  Cortesi, Enrico ^a   Grifalchi, Federico ^a   Ramponi, Sara ^a   Padovani, Augusto ^a   Mancuso, Andrea ^a   Paoluzzi, Luca ^a   Ferrau, Francesco ^b   Oliva, Annalisa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b S Vincenzo Hospital   (Italy)

Author keywords

Fluorouracil; Metastatic breast cancer; Paclitaxel; Phase I

Indexed keywords

FLUOROURACIL; PACLITAXEL;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; METASTASIS; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TOXICITY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 0037862041     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Seidman AD, Tiersten A, Hudis C et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast. J Clin Oncol 13: 2575-2581, 1995.
2. Seidman AD, Reichman BS, Crown JP et al.: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995.
3. Fountzilas G, Athanassiades A, Giannakakis T et al.: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32: 47-51a, 1996.
4. Gianni L, Munzone E, Capri G et al.: Paclitaxel in metastatic breast cancer: a trial of two doses by 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169-1175, 1995.
5. Vici P, Conti F, Di Lauro L et al.: Paclitaxel in anthracyclines-resistant breast cancer patients. Proc Am Soc Clin Oncol 16: 196a, 1997.
6. Chu L, Sutton LM, Peterson BL and Havlin KA: Continuous infusion of 5 Fluorouracil as first line therapy for metastatic breast cancer. J Infusional Chemotherapy 6/4 1996.
7. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y and Adachi KI: Schedule-dependent interaction between Paclitaxel and 5-Fluorouracil in human carcinoma cell lines in vitro. British J Cancer 74: 704-710, 1996.
8. Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z and Buzdar AU: Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol 24(4 Suppl 11): S11-13-S11-19, 1997.
9. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S and Weil C: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 15: 1707-1715, 2001.
10. Meluch AA, Greco FA, Burris HA, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V and Hainsworth JD: Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 15: 3018-3024, 2001.
11. Seidman AD, Hudis CA, Albanel J et al.: Dose-dense therapy with weekly 1-hour paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998.
12. Huizing MT, Keung CF, Rosing H et al.: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pre-treated ovarian cancer patients. J Clin Oncol 11: n11, 1993.
13. Konishi K, Tani Y et al.: Pharmacokinetic Comparison between weekly paclitaxel treatment and by 3 weeks treatment in patients with metastatic breast cancer. Proc Am Soc Clin Onc 2001: 21, 2000.
14. Luck HJ, Marhenke D, Petry KU et al.: Weekly paclitaxel monotherapy as salvage treatment in pre-treated patients with metastatic breast cancer: experience with 1-hour schedule. Breast Cancer Res Treat 46: 59a, 1997.
15. Perez A, Vogel CL, Irwin DH et al.: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19: 4216-4223, 2001.
16. Breier S, Lebedinsky C, Ayaviri C, Roffe C et al.: Long term weekly paclitaxel over 1 hour infusion with de-escalated premedication. A phase II trial report. Breast Cancer Res Treat 1(57), 1999.
17. Sikov W, Akerley W, Strenger R et al.: Weekly high-dose paclitaxel demonstrates significant activity in advanced breast cancer. Proc Am Soc Clin Oncol 17: 112a, 1998.
18. Regazzoni S, Pesce G, Marini G, Cavalli F and Goldhirsch A: Low dose continuous intravenous infusion of 5 Fluorouracil for metastatic breast cancer. Annals of Oncology, 7/8 1996.
19. Ragaz J, Campbell C, Gelmon K, Tolcher T, Bryce C and O'Reilly S: Can patients with metastatic breast cancer pre-treated with Cyclophosphamide, Anthracyclines or Taxol respond to infusions of 5FU' rationale for FUI-containing chemotherapy regimens. Full Journal Title: 20th Annual San Antonio Breast Cancer Symposium on Breast Cancer Research and Treatment, San Antonio, Texas, USA, 1997.
20. Klaassen U, Wilke H and Seeber S: Weekly high-dose infusional 5-Fluorouracil combination in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid alone and in combination with paclitaxel and cisplatin. J Infus Chemother 6: 127-, 1996.
21. Nicholson B, Paul D, Shyr Y, Garret M et al.: Paclitaxel/5-Fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center Phase II Trial. Seminars in Oncology. 24/5 Suppl. 11 (S11 20-S11 23) 1997.
22. Hudis C: Dose-dense chemotherapy for breast cancer: the story so far. Br J Can 82 (12): 1897-1899, 2000.
23. Loesch, Robert NJ, Keller AM et al.: Phase II trial multicenter of a weekly taxol, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer. Proc Am Soc Clin Onc 17: 593, 1998.
24. Castiglione F, Venturino A et al.: a weekly schedule of 5FU 24 hours infusion, Folinic Acid and Paclitaxel for advanced breast cancer. Proc Am Soc Clin Oncol 2001; 21: 1992.
25. Luck HJ, Scholz U, Kuhnle H et al.: UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer. Oncology 13(7 Suppl 3): 74-6, 1999.